.png){kind=icon}
.png){kind=icon}
Return
Gut microbiota and metabolites in remodeling the tumor microenvironment and regulating immunotherapeutic efficacy in colorectal cancer
.png){kind=icon}
PRE
AI
M
Z
F
Y
Z
Z
P
DOI：10.1016/j.lfs.2026.124581.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Immune checkpoint inhibitors (ICIs) benefit patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), but efficacy remains limited in proficient mismatch repair/microsatellite-stable (pMMR/MSS) tumors. This review evaluates how the gut microbiota and microbial metabolites influence CRC development, the tumor microenvironment, and immunotherapy responses, with emphasis on strategies for pMMR/MSS CRC.
Keywords:
Colorectal cancer
Gut microbiota
Metabolites
Tumor microenvironment
Immunotherapy
Journal
IF:
5.1
Papers:
1.7W
Citations:
4.7W
Organization
Cited Papers